ADR-529

Known as: ADR 529, ADR529 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1990-2006
024619902006

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1996
1996
Dexrazoxane [(DZR), ADR 529, ICRF-187] ameliorates doxorubicin (DOX)-induced cardiotoxicity in animals, and is recommended as a… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
1994
1994
Certain bis(2,6-dioxopiperazine) derivatives, which include ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl]propane; ADR-529) and… (More)
Is this relevant?
1993
1993
The effect of the bisdioxopiperazine cardioprotector ICRF-187 (ADR-529, dexrazoxan) on drug-induced DNA damage and cytotoxicity… (More)
Is this relevant?
1992
1992
BACKGROUND Although doxorubicin is an anticancer agent with a wide spectrum of activity, therapy with this anthracycline must… (More)
Is this relevant?
1992
1992
In this study doxorubicin, epirubicin, and mitoxantrone were compared for their cardiotoxic potential in a chronic mouse model in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1992
1992
The purpose of this study was to evaluate the optimal timing of ADR-529 administration to protect rats treated with doxorubicin… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
1992
1992
ADR-529 protects against anthracycline cardiotoxicity, possibly by preventing free radical induction. We hypothesize that this… (More)
Is this relevant?
1992
1992
An HPLC method using electrochemical detection (ED) has been validated for the determination of ADR-529 in plasma and urine using… (More)
Is this relevant?
1990
1990
ADR-529 [(+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane], a nonpolar, cyclic analogue of EDTA, protects against anthracycline… (More)
Is this relevant?
Review
1990
Review
1990
Anthracyclines are powerful anticancer drugs whose use is limited by the development of chronic cardiotoxicity. The… (More)
Is this relevant?